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Abstract 
Background and Aims: The expression of pancreatic-duodenal homeobox 1 (PDX1) 
in gastric cancer is aberrantly reduced. The aim of this study was to elucidate the 
regulation of DNA methylation and histone acetylation at the promoter for PDX1 
silencing in gastric cancer.   
Methods: PDX1 expression in response to demethylation and acetylation was 
detected in human gastric cancer cell lines by RT-PCR and Western blot. Four CpG 
islands within the 5’-flanking region of PDX1 gene were analyzed with their 
transcription activities being detected by dual luciferase assay. Promoter 
hypermethylation was identified in gastric cancer cell lines and cancer tissues by 
methylation-specific PCR (MSP) or bisulfite DNA sequencing PCR analysis (BSP). 
Histone acetylation was determined by chromatin immunoprecipitation (ChIP) assay.  
Results: Demethylation by 5-aza-2'-deoxycytidine (5’-aza-dC) and/or acetylation by 
Trichostatin A (TSA) restored PDX1 expression in gastric cancer cells. 
Hypermethylation was found in four CpG islands in 6 of 7 cancer cell lines. However, 
only the distal CpG island located in the promoter fragment of PDX1, F383 (c.-2063 ~ 
-1681nt upstream of the ATG start codon) displayed significant transcriptional 
activity that could be suppressed by SssI methylase and increased by 5’-aza-dC and 
TSA. More than 70% of the single CpG sites in F383 were methylated with 
hypermethylation of F383 fragment more common in gastric cancerous tissues 
compared to the paired normal tissues (p<0.05). ChIP assay showed F383 was also 
associated with low hypoacetylation level of the histones.       
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Conclusion: Promoter hypermethylation and histone hypoacetylation contribute to 
PDX1 silencing in gastric cancer.    
 
Keywords: PDX1, gastric cancer, DNA methylation, histone acetylation     
 
Abbreviation: PDX1, pancreatic-duodenal homeobox 1; 5’-aza-dC, 
5’-aza-2'-deoxycytidine; TSA, trichostatin A; MSP, methylation-specific PCR; BSP, 
bisulfite DNA sequencing PCR analysis; ChIP, chromatin immunoprecipitation; 
DNMT, DNA methyltransferase; HAT, histone acetyltransferase; HDAC, histone 
deacetylase; q-RT-PCR, quantitative real-time reverse transcription PCR; USF1, 
upstream stimulatory factor 1; Ptf1α, pancreas transcription factor 1α; HNF3β, 
hepatocyte nuclear factor 3β; IUGR, intrauterine growth retardation; HSS, nuclease 
hypersensitive sites.  
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Introduction 
In mammals, epigenetic regulation including DNA hypermethylation and histone 
modification represents the major epigenetic mechanisms implicated in regulation of 
gene transcription [1]. DNA methylation within the promoter of tumor suppressor 
genes is a common phenomenon in cancer cells. It results in the transcriptional 
silencing of these genes and promotes tumor development [1-4]. Promoter 
hypermethylation has been reported to induce aberrant reduction of some homeobox 
genes such as Aristaless-like homeobox-4[5], CDX1[6-8] and CDX2[9] in cancers 
including squamous esophageal cancer, hematologic malignancies and colorectal 
cancers.    
Histone acetylation/deacetylation alters the status of open chromatin domains and thus 
affects gene transcription. This process is modulated by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). Loss of histone H3 and H4 acetylation 
attributes to the imbalanced recruitment of HDAC and results in transcription 
repression of tumor suppressors in cancers [10].  
Pancreatic duodenal homeobox-1 (PDX1) is a homeobox gene that belongs to the 
ParaHox subfamily [11, 12]. PDX1 plays a critical role in embryogenesis and tissue 
differentiation[13-18]. During the development of mice embryos, deletion or mutation 
of pdx1 gene allele resulted in pancreatic malformation[17,18]. In pdx1-null mice 
embryos, the malformations of the stomach-duodenum junction caused the lack of 
gastric empty and subsequent stomach distension [16]. The cell-type specific 
expression of PDX1 is controlled by 5’-flanking sequences that contain several 
5 
 
conserved promoter regions [19-21]. Area I (-2852 to -2547) and II (-2247 to -2071) 
direct endocrine cell expression [19,20] while area III (-1973 to -1694) directs the 
transient expression in β-cells [22, 23]. Our previous work has implicated PDX1 as a 
putative tumor suppressor with reduced expression in gastric cancer [24,25].  
In this project, we investigated the epigenetic regulatory mechanism of PDX1 gene in 
gastric cancer. We showed that both promoter hypermethylation and histone 
deacetylation accounted for PDX1 silencing. Unlike the responsive sequences around 
the translation starting codon identified in β-cells [26], a functional fragment, F383, 
located at area III (-2063 to -1681) mediated the epigenetic regulation of PDX1 in 
gastric cancer cells. 
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Methods and Materials   
Cell Lines and Tissue Samples   
Human gastric cancer cell lines AGS, KATOIII, SNU1 were from the American Type 
Culture Collection (Manassas, VA). SGC7901 was from the Academy of Military 
Medical Science (Beijing, China), TMK1, MKN45 and BCG823 were maintained in 
our lab and described in the previous study [24, 27, 28]. All cell lines were grown as 
described previously[24]. 30 pairs of human gastric cancerous tissues with the 
adjacent normal tissues were collected from the specimen archives of the Department 
of Gastroenterology, the Affiliated Hospital of Sun Yat-sen University. CpGnome 
universal methylated DNA (Invitrogen, Carlsbad, CA) was used as the positive 
control for methylation.    
 
Reverse Transcription Polymerase Chain Reaction     
As per the manufacturer’s protocol, Mini-RNease RNA extraction kit (Qiagen, Hilden, 
Germany) and Thermoscript RT system reagent (Gibco BRL, Gaithersburg MD) were 
used for RNA extraction and reverse transcription. PCR was performed using 2μl 
cDNA template, 0.2U Hot-start Taq DNA Polymerase ,forward and reverse primers 
and dNTPs Mix in a final volume of 20μl. The sequences of PDX1 primers were 
shown in our previous publication [24]. And PCR was carried out for 35 cycle with 
94  denaturation for 30 seconds, 56℃ ℃ annealing for 30 seconds and 72℃ elongation 
for 45 seconds.      
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Western Blot   
Whole cell lysates were prepared and assayed for protein expression by western blot 
as reported previously[24]. Immunoblots were developed and visualized by the 
enhanced chemiluminescence (ECL) system (Amersham, Piscataway, NJ) according 
to the manufacturer’s protocol. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used as the internal loading control.    
 
5’-aza-dC and TSA Treatment    
Cancer cells were seeded in 6-well plates at a density of 2 x 10
5
 cells per well 12 
hours before the drug treatment. The cells were treated with the following drugs alone 
or in combination: 5’-aza-dC (5, 10 or 20μM, Sigma, St Louis, MO) and TSA (500 
nM, Sigma). Cells were harvested after 24 hours. Double diluted water (DDW) was 
used as the dissolvent control.  
 
Construction of Putative Promoter Fragments    
To indentify functional CpG islands and evaluate the association of DNA methylation 
and promoter transcription, the CpG islands of the PDX1 promoter had to be 
identified. We searched PDX1 genomic sequence at -2000nt to +600nt using Promoter 
Database (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home) and found four 
enriched CpG islands by MethPrimer 
(http://www.urogene.org/methprimer/index1.html). The four islands were respectively 
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located at -1975 to -1704 (island 1), -1226 to -1066 (island 2), -818 to -694 (island 3), 
and -112 to +521 (island 4) (Fig.2a). Then four fragments containing these putative 
CpG islands were amplified and inserted into the firefly luciferase reporter vector, 
pGL3basic (Promega, Madison, WI). A XhoI site was added into the 5’ terminus of the 
forward primers and Hind III site was added to the reverse primer. With the upstream 
nucleotide adjacent to the ATG translation start codon, henceforth defined as c.1, the 
four reporter constructs were named F383 (-2063 to -1681), F314 (-1320 to -1007), 
F283 (-864 to -583) and F724 (-170 to +545), respectively. The cloned fragments were 
all verified by restriction enzyme digestion and sequencing. All primers for 
construction of the PDX1 promoter were designed according to the genomic sequence 
of the PDX1 gene (accession no. NC_000013.9) published in GenBank with their 
sequences being listed in Supplementary Table 1.   
 
Transient Transfection, In Vitro Methylation, and Luciferase Reporter Assay  
Reporter constructs F383, F314, F283 and F724 (0.8 µg/well) were transfected into 
cells pre-seeded into 24-well tissue culture plate by Lipofectamine 2000 (Invitrogen). 
Empty pGL3basic vector was used as control while PRL-CMV (0.008 µg /well, 
Promega) was used to normalize the reporter gene. 24 hours after transfection, cells 
were harvested and firefly luciferase activities were measured using the 
Dual-Luciferase reporter assay system (Promega) with a model TD-20/20 
Luminometer (EG&G Berthold, Australia). The value of firefly luciferase activity was 
normalized to that of renilla luciferase. Promoter activity was presented as the fold 
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change of relative luciferase unit (RLU) compared to the basic vector control. RLU 
equals the value of the firefly luciferase unit, divided by the value of the renilla. Each 
experiment was performed in triplicate, and at least 3 sets of independent transfection 
experiments were performed. SssI methylase, which is capable of non-specifically 
methylating all CpG dinucleotides, was used for the in vitro methylation of putative 
promoter fragments. In each case, 3 μg of plasmid DNA (triplicates in 24-well plate), 
pGL3basic and all reporter constructs were incubated in a 20μl reaction system 
containing 4 units of SssI methylase, 2μl of 20 x S-adenosylmethionine and 2μl of 10 
x NEBuffer for 4 hours at 37℃ followed by 20 minutes at 65℃to stop the reaction.  
 
Genomic DNA Isolation, Bisulfite DNA Sequencing PCR Analysis (BSP) and 
Methylation Specific PCR Analysis (MSP)   
Genomic DNAs were isolated from cells or resected specimens using DNeasy Blood 
& Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
DNA samples were treated with sodium bisulfite to convert cytosine to uracil. Briefly, 
1.0 μg of genomic DNA from each sample was denatured with 2 mol/L NaOH at 
37  ℃ for 10 minutes, followed by incubation with 3 mol/L sodium bisulfate (pH 5.0, 
Sigma) at 50  ℃ for 16 hours, Two microliters of 20 μl bisulfite-treated DNA was 
amplified at 95  ℃ for 20 minutes and then 40 cycles at 94  ℃ for 30 seconds, 52  ℃ for 
30 seconds, and 72  ℃ for 45 seconds and a final extension at 72  ℃ for 10 minutes 
using the bisulfate treated DNA sequencing PCR (BSP) primers (Supplementary 
Table 2). For cell lines, PCR products were purified and then inserted into pGEM-T 
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vector (Promega); 10-12 white clones were selected for each sample and then 
sequenced to determine the aberrant methylation of each CpG island. Moreover, 2 
normal gastric tissues were used as normal controls.  
Methylation status of human gastric cancerous tissues and paired normal tissues was 
evaluated by MSP analysis. After isolation and modification with sodium bisulfite, 
genomic DNA samples were amplified with methylation or unmethylation specific 
primers with their sequences listed in supplementary table 2. The total 25μl PCR 
reaction contained 10pmol/L primers, 25μmol/L deoxynucleoside triphosphates, 2μl 
of bisulfate-treated DNA, 0.5U of hot-start Taq polymerase, and the respective buffers. 
The condition for PCR amplification was as follows: 20-minute hot start at 95℃ 
followed by 40 cycles at 94  ℃ for 30 seconds,52  ℃ for 30 seconds,72  ℃ for 45 
seconds and a final extension at 72  ℃ for 10 minutes. PCR products were visualized 
on a 2% agarose gels stained with ethidium bromide. Moreover, a normal gastric 
tissue was used as normal control.  
 
Chromatin Immunoprecipitaion (ChIP) and Quantitative Real-time Reverse 
Transcription PCR (q-RT PCR) 
Evaluation of histone acetylation levels was performed using a ChIP assay with a 
commercially available kit (Upstate Biotechnologies, Charlottesville, VA) according 
to the manufacturer’s protocol. Approximately 2 x106 cells were treated with 1% 
formaldehyde to cross-link the protein to DNA for 15 min at 37℃. After washing, the 
cell pellets were resuspended in lysis buffer and sonicated to yield an average DNA 
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size of about 500bp. The sonicated cells were subsequently deposited by 
centrifugation and diluted with ChIP dilution buffer. 20µl of the diluted lysates was 
left as the input control. Samples were incubated with protein A-Sepharose and 
sonicated salmon sperm DNA for 1 hour at 4℃, then incubated with 5μg specific 
antibodies against acetyl-histone H3 (lys 9 and 14) and acetyl-histone H4 (lys 5, 8, 12 
and 16) (Upstate Biotechnology), or normal rabbit IgG (Santa Cruz Biotechnology ) 
overnight at 4℃ followed by incubation with Protein A-Sepharose for 1 hour. After 
washing, the sepharose/antibody/histone complexes were eluted with elution buffer 
(1% SDS and 0.1 M NaHCO3). The cross-linking was then reversed by 5M NaCl at 
65℃ for 4 hour. The DNAs were extracted with phenol/chloroform, precipitated with 
ethanol and applied for quantitative analysis by q-RT PCR.  
q-RT PCR reactions were performed for 60 cycles with 94℃ for 15 seconds,58℃ for 
15 seconds, and 72℃ for 40 seconds by using Applied Biosystems Sequence 
Detection System 7900 (ABI Prism 7900HT, Applied Biosystems, California, USA) 
in 20μl mixture including 10μl power SYBR GREEN PCR Master Mix (Applied 
Biosystems, Foster City, CA). Inspection of melt curves and CT values generated 
were used for quantification of the copy numbers of four fragments and the results 
were expressed as the fold change compared to that obtained with IgG. The primer 
sequences are listed in Supplementary Table 3. The amount of immunoprecipitated 
DNA was normalized to the input DNA. Each treatment was set up in triplicate, and 
two independent ChIP experiments were performed.   
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Statistical Analysis  
The results of luciferase activities are expressed as mean ± SEM. Student t test and 
Fisher’s Exact Test were used to determine the statistical significance between different 
groups by the statistical software, SPSS13.0. A p value of less than 0.05 was 
considered significant.   
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Results   
Restoration of PDX1 expression in cancer cells by demethylation and acetylation 
We have reported that PDX1 expression in gastric cancer cells is down-regulated [24]. 
To examine if epigenetic regulation was involved in PDX1 silencing, we first treated 7 
gastric cancer cell lines with 5’-aza-dC. As shown in Figure 1A, the endogenous 
mRNA expression of PDX1 in gastric cancer cells was weak and partly up-regulated 
by 5’-aza-dC in these cell lines. Similarly, PDX1 expression could be up-regulated by 
the HDAC inhibitor, TSA (Figure 1B). Furthermore, 5’-aza-dC and TSA could 
increase PDX1 expression in a dose dependent manner (Figure 1C). To evaluate the 
interaction of 5’-aza-dC and TSA on PDX1 expression, we randomly chose the two 
cell lines TMK1 and KATOIII. As shown in Figure 1D and E, a slightly synergistic 
effect was observed when cells were treated with combination of 5’-aza-dC and TSA. 
These results suggested that PDX1 expression in gastric cancer cells was modulated 
by epigenetic regulation that included both DNA methylation and histone 
deacetylation.   
 
Hypermethylation of PDX1 promoter in gastric cancer cell lines   
To define the putative responsive sequence for epigenetic regulation, we first searched 
a 2600bp genomic sequence including the ATG translation starting codon (-2000nt to 
+600nt) of the PDX1 gene using Methprimer software (http://www.ucsf.edu/urogene 
/methprimer). Four putative CpG islands were found located at -1975nt to -1704nt, 
-1226nt to -1066nt, -818nt to -694nt and -112nt to +521nt, respectively (Figure 2A). 
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We then examined the methylation status of these CpG islands in 7 gastric cancer cell 
lines by MSP assay. Complete methylation in all four CpG islands was found in 
SGC7901, AGS, TMK1 and SNU1 cells while partial methylation was found in all 
CpG islands except F383 in BCG823 and MKN45 cells. However, we showed no 
DNA methylation of all four islands examined in KATOIII cells as well as in normal 
gastric tissue (Figure 2B). To confirm the accuracy of the MSP methodology, we 
treated TMK1 cells with 5’-aza-dC. We found that the complete methylation in all 
four CpG islands was successfully reversed into partial methylation (Figure 2C). 
These results suggested that hypermethylation of PDX1 promoter existed in most of 
gastric cancer cell lines.   
 
Identification of a functional CpG island within the 5’-flanking region of PDX1 
gene   
To determine if the sequences contained by CpG islands were critical for PDX1 
transcription, we cloned these fragments into pGL3basic vector to generate 4 
luciferase reporter constructs, F383, F314, F283 and F724. After transient transfection 
into cells, a dual luciferase assay showed that F383, the most distal fragment 
displayed substantial promoter activity in all three cell lines tested (Figure 3A). This 
fragment was included in promoter Area III described previously (19, 20). The RLU 
of F383 in AGS, TMK1 and KATOIII cells were 14.37 ± 3.38, 14.51 ± 4.12 and 11.32 
± 0.17, respectively. On the contrary, the transcription activities of F314, F283 and 
F724 were not significantly different from that of pGL3basic vector (Figure 3A). 
15 
 
Subsequently, we evaluated the effect of in vitro methylation and demethylation on 
transcription activity of F383. As shown in figure 3B, in vitro methylation by 
treatment with SssI methylase reduced the promoter activities of F383 by 0.52 ± 0.05 
times in AGS cells (p<0.01), 0.68 ± 0.001 times in TMK1 cells (p<0.05) and 0.25 ± 
0.03 times in KATOIII cells (p<0.001). Consistent with this, in vitro demethylation by 
pretreatment with 5’-aza-dC increased the promoter activities of F383 to 1.47 ± 0.10 
fold in AGS cells (p<0.001), 1.02 ± 0.08 fold in TMK1 cells (p>0.05), and 1.01 ± 0.06 
fold in KATOIII cells (p>0.05). The promoter activity of F383 was slightly increased 
in TMK1 cells might attribute to non-specificity of 5’-aza-dC treatment. However, the 
promoter activity of F383 didn’t changed with 5’-aza-dC because none of the four 
CpG islands studied are methylated in the KATOIII cells. In general, these results 
indicate that the distal CpG island located at -1975nt to -1704nt, contained by F383, 
was not only critical for PDX1 transcription but also the responsive sequence for DNA 
methylation.    
 
Hypermethylaiton of CpG dinucleotides within F383 fragment    
Next, we analyzed the methylation status of CpG dinucleotides within the F383 
fragment using BSP analysis. As shown in figure 4A (wildtype sequence), 17 CpG 
sites were presented in this fragment. All of them were candidate sites for methylation 
since none of them was altered into T after bisulfite modification (Figure 1A, 
modified sequence). Again no methylation was found in all 17 CpG sites in KATOIII 
cells, and all other cell lines displayed high levels of methylation in the 17 CpG sites. 
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As low as 1.96% ± 1.24% and 0.98% ± 0.97% of methylation were found in the two 
normal tissues (p<0.0001 compared to cancer cell lines, Figure 4B and C). The 
detailed methylation ratios for the 17 CpG dinucleotides in 7 gastric cancer cell lines 
were listed in supplement table 4. Only a few showed methylation at the third (8.3%) 
and the 13th CpG site (16.7%) in the two normal gastric tissues, however, the 
significant higher methylation ratios for the 17 CpG dinucleotides in 7 gastric cancer 
cell lines were examined (Supplement table 4).   
 
Aberrant hypermethylation of F383 in gastric cancerous tissues  
To validate our in vitro findings, we analyzed the methylation status of F383 in 30 
pairs of gastric cancerous tissues and their matched adjacent normal tissues by MSP 
assay(Figure 5). In adjacent normal tissues, F383 was unmethylated in 16 (53.3%) 
samples and partially methylated in another 14 (46.7%) samples. In gastric cancer, 
F383 was completely methylated in 3 (10%) samples and partially methylated in 
another 27 (90%) samples (vs adjacent normal control, p<0.001). Further analysis 
indicated that the 3 gastric cancer tissues with complete methylation were all 
intestinal type and at advanced stages.   
 
Role of histone acetylation in PDX1 transcription 
To characterize the role of acetylation in PDX1 silencing, we detected the association 
between PDX1 promoter and acetylated histones using ChIP assay followed by 
q-RT-PCR. We showed that F314, F283 and F724 fragments, which had no obvious 
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promoter activity (Figure 3A), could all bind to acetylated histone H3 and H4,most 
notably in TMK1 cells (Figure 6A). However, the association between these 
fragments and acetylated histones in KATOIII cells were at low levels (Figure 6A). 
This finding indicated the presence of hypoacetylation in KATOIII cells but not in 
TMK1 cells in these promoter areas. Regarding F383, its association with acetylated 
histone H3 or H4 were absent or only at low levels in both cell lines (Figure 6A), 
suggesting F383 is a common fragment for deacetylated regulation in both cell lines. 
To further confirm this finding, we examined the association between acetylated 
histones and F383 in cells treated with TSA. We found that the level of histone H3 
and histone H4 associated with F383 was significantly increased by TSA. The fold 
change of acetylated H3 and H4 were 249.60 ± 17.27 and 1.84 ± 0.09 in TMK1 cells 
and 3.92 ± 0.11 and 4.06 ± 0.11 in KATOIII cells (p<0.05, Figure 6B). Finally, we 
treated the reporter constructs of F383 with TSA in vitro. We showed that TSA 
upregulated the transcription activity of F383 to as high as 8.70 ± 0.04 folds in 
KATOIII cells (p<0.001, Figure 6C). These findings suggest that this fragment is an 
important responsive sequence for histone deacetylation.    
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Discussion 
PDX1 is a critical regulator for the development and differentiation of some endocrine 
tissues. Several transcription factors such as USF1 (upstream stimulatory factor 1) 
[29], HNF3β (hepatocyte nuclear factor3β) [19] and Ptf1α (Pancreas transcription 
factor 1α) [21,22] were capable of stimulating PDX1 transcription in β-cells [19-23, 
29]. Here we reported that promoter methylation and histone acetylation accounted 
for PDX1 gene silencing in gastric cancer. A functional fragment, F383, located 
within the PDX1 promoter area III (-2063 to -1681) mediated the epigenetic 
regulation of PDX1. PDX1 expression could be effectively restored by reversing 
promoter methylation and histone deacetylation. This supports our previous finding 
that PDX1 was a novel tumor suppressor for gastric cancer [24].  
Typical promoter methylation is restricted to cytosines in CpG dinucleotides located 
within CpG islands. Through bioinformatic analysis, we identified four putative CpG 
islands. Island 1 (-1975 ~ -1704), 2 (-1226 ~ -1066) and 4 (-112 ~ +521) were all 
located within or near the three nuclease hypersensitive sites (HSSs) [19,20]. In 
previous studies the HSS sites were located between -2560 and -1880 (HSS1), -1330 
and -800 (HSS2), and -260 and +180 (HSS3), respectively [19,20]. Thus, these 
fragments should be the acting fragments for PDX1 transcription. Similarly, MSP also 
revealed complete methylation can be seen in tumor cells, albeit only a small 
percentage, however it not at all seen in normal cells. Also completely unmethylated 
F383 could be seen in normal cells but not at all seen in tumor cells. Partial 
methylation was much higher in tumor as compared to normal cells. This speaks to 
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the process by which aberrant methylation occured in cancer development continuum, 
supporting it was a well candidate for epigenetic regulation. This finding was partially 
supported by a recent publication in which a proximal CpG island (-360 to +200) was 
methylated and responsible for the pdx1 permanent silencing in β-cells of rat with 
IUGR [26].  
To further assess the biological function of these CpG islands, we evaluated the 
transcriptional activities of reporter constructs. Only the most distal island (F383) 
displayed significant promoter activity. F314, F283 and F724 were associated with 
histone hypoacetylation in KATOIII cells but exerted no transcriptional activities. 
This suggested that the epigenetic modifications in CpG island 2, 3 and 4 were not 
essential for PDX1 transcription. There were three possible interpretations for this 
phenomenon. Firstly, island 2, 3 and 4 were located beyond the active promoter area 
of PDX1 while F383 was located within the well-defined promoter fragment, area III, 
described previously [19,20]. Secondly, island 2, 3 and 4 were located in the center of 
HSS2 and HSS3 while HSS sites were most likely occupied by non-histone proteins 
(transcription factors). This point was supported by our finding that TSA treatment 
could only increase the transcriptional activity of F383 but not the other three 
fragments. Lastly, the transcription factors might antagonize the suppressive effect of 
epigenetic regulation. Although the transcription factors for islands 2 and 3 were 
unknown, a positive regulator USF1 could bind to its responsive element located at 
island 4 to stimulate PDX1 expression in β-cells [29]. A recent study reported 
recruitment of the histone deacetylase 1 (HDAC1) and deacetylation of histones H3 
and H4 were associated with loss of USF-1 binding at the proximal promoter of Pdx1 
and subsequently resulted to pdx1 silencing in the rat fetal with IUGR [26].   
Nevertheless, The CpG island at F383 fragment must not be the only methylated 
functional sequence of PDX1 gene. No methylation was found in this island in 
KATOIII cells, and promoter activity of F383 didn’t significantly regulated by SssI 
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methylase or 5’-aza-dC. However, PDX1 expression in this cell line could be 
upregulated as well by 5’-aza-dC and/or TSA (Figure 1). We proposed that the effect 
may be mediated by the methylation of scatter single CpG sites we have not defined 
here. Similarly, our previous study reported that single CpG site but not CpG island 
attributes to XAF1 transcription silencing in gastrointestinal cancer cells[28]. Further, 
F383 might be not the only promoter sequence regulating PDX1 expression in 
KATOIII cells. Recent study reported that conserved area IV at -6200nt to -5670nt 
from 5’-flanking sequence also regulated pdx1 transcription [21]. Area IV was an 
upstream control region in the rat pdx-1 gene located between -6200nt and -5670nt, 
which is also present in the human gene. So area IV might be a putative promoter, 
containing a hypermethylated CpG island and regulate PDX1 expression in KATOIII 
cells.   
In conclusion, epigenetic regulation including promoter methylation and histone 
deacetylation contributed to PDX1 silencing in gastric cancer cells with the 
predominant responsive sequences (-2063 to -1681) localising to the PDX1 promoter 
area III.   
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Figures Legends 
Figure 1. Restoration of PDX1 expression in cancer cells by demethylation and 
acetylation. A, gastric cancer cell lines were treated with double diluted water 
(DDW),the dissolvent control (C) or 5µM 5’-aza-dC (A) for 24 hours. B, gastric 
cancer cell lines were treated with DDW (C) or 500nM TSA (T) for 24 hours. PDX1 
mRNA expression was detected by RT-PCR with GAPDH being used as the internal 
control. C, Cancer cells were treated with the indicated concentration of 5’-aza-dC or 
TSA for 24 hrs, PDX1 and GAPDH expressions were detected by RT-PCR. D & E, 
TMK1 and KATOIII cells were treated with 5’-aza-dC and TSA alone or in 
combination for 24 hours, PDX1 mRNA and protein expressions were detected by 
RT-PCR (D) and western blot (E). GAPDH was used as an internal control. All of 
these pictures were representatives of three to four independent experiments with 
similar findings.   
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Figure 2. Hypermethylation of CpG islands of the PDX1 gene in cancer cell lines. 
A, The schematic diagram of putative CpG islands within the PDX1 promoter 
identified by bioinformatics analysis. The axis is the percentage of the dinucleotide, 
guanine and cytosine. The genomic DNA sequences (-2000nt to +600nt) of PDX1 was 
analyzed by Methprimer software. Locations of 4 putative CpG islands were 
displayed in areas with gray shadow. B, MSP result of four putative CpG islands in 7 
gastric cancer cell lines and one normal gastric tissue. M, methylated; U, 
unmethylated. C, Alteration of methylation status in TMK1 cells induced by 
5’-aza-dC.  
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Figure 3. Identification of a functional CpG island within the 5’-flanking region 
of the PDX1 gene. A, The four reporter constructs were transfected transiently into 
AGS, TMK1 and KATOIII cells and dual luciferase assays were performed to assess 
their transcriptional activities. Firefly luciferase activity were normalized to renilla 
activity. Promoter activity was presented as the fold change of relative luciferase unit 
(RLU) compared to the pGL3basic vector. RLU equals the value of the firefly 
luciferase unit, divided by the value of the renilla. This result was expressed as the 
mean of triplicate treatments ± standard deviation. B, Reporter construct F383 was 
transfected into cells in absence or presence of SssI methylase (4U) and 5’-aza-dC. 
(5µM). Transcriptional activities were assessed by dual-luciferase assays (* p < 0.05, 
** p < 0.01, *** p < 0.001, vs control). The RLUs of SssI methylase and 5’-aza-dC 
were normalized to that of the non-treatment control (Ctrl). All of these experiments 
were repeated for three to four times with identical results.   
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Figure 4. Methylation status of CpG sites within the functional promoter 
fragment. Fragment F383 was amplified using bisulfite-modified genomic DNA as 
template and inserted into pGEM-T4 vector. Ten to 12 white clones for each cell line 
were selected for sequencing. A, Wildtype and modified sequence of F383 in 
BCG823 cells. The BSP primer sequences were underlined and the methylated CpG 
dinucleotides that were unable to be altered by bisulfite modification were labeled in 
bold and italicise. B, Methylation status of the 17 CpG dinucleotides within F383 
fragment in cancer cell lines. C, Percentage of methylated CpG sites within F383 in 
cancer cell lines. 1N & 2N, normal gastric tissues. *p < 0.0001 vs either 1N or 2N.   
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Figure 5. Hypermethylation of the PDX1 promoter in gastric cancerous tissues. A, 
The methylation status of F383 in 30 pairs of gastric cancer (T) and their adjacent 
normal (N) tissues was analyzed by MSP. M, methylated; U, unmethylated. PC, 
positive control. These figures were the representatives of three independent 
experiments using the same DNA sample with repeatable results. B, Percentage of 
methylated F383 fragment in gastric cancerous tissues and their adjacent normal 
tissues, p < 0.001 between cancerous and normal tissues.    
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Figure 6. Role of histone acetylation in PDX1 transcription. A, Cross-linked and 
sonicated lysates of TMK1 and KATOIII cells were immuno-precipitated with 
anti-acetyl-histone H3 and H4 antibodies. Different promoter fragments of PDX1 
were amplified quantitatively by q-RT-PCR. Rabbit IgG was used as the antibody 
control. The result was expressed as the fold induction compared to that of IgG (* p < 
0.05, **p < 0.01 vs IgG control). B, TMK1 and KATOIII cells were treated with TSA 
(500nM) or DDW, the dissolvent control (Ctrl). PDX1-associated histone acetylation 
was detected by ChIP and q-RT-PCR (* p <0.05, **p < 0.01, compared to ctrl). C, 
F383 was transfected into KATOIII cells in presence of TSA (500 nM) or the 
dissolvent control (Ctrl). Transcriptional activities were assessed by dual-luciferase 
assay (*** p < 0.001, vs control).   
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